A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)–associated Nephritis Versus Myeloperoxidase ANCA–associated Nephritis

REFERENCES

1. 1.↵
   1. Mohammad AJ,
   2. Jacobsson LT,
   3. Westman KW,
   4. Sturfelt G,
   5. Segelmark M

   . Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 2009;48:1560–5.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Watts RA,
   2. Scott DG,
   3. Jayne DR,
   4. Ito-Ihara T,
   5. Muso E,
   6. Fujimoto S,
   7. et al.

   Renal vasculitis in Japan and the UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008;23:3928–31.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Jennette JC,
   2. Falk RJ,
   3. Bacon PA,
   4. Basu N,
   5. Cid MC,
   6. Ferrario F,
   7. et al.

   2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Lyons PA,
   2. Rayner TF,
   3. Trivedi S,
   4. Holle JU,
   5. Watts RA,
   6. Jayne DR,
   7. et al.

   Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214–23.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Lionaki S,
   2. Blyth ER,
   3. Hogan SL,
   4. Hu Y,
   5. Senior BA,
   6. Jennette CE,
   7. et al.

   Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452–62.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mohammad AJ,
   2. Jacobsson LT,
   3. Mahr AD,
   4. Sturfelt G,
   5. Segelmark M

   . Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology 2007;46:1329–37.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Statistics Sweden

   . Population data. [Internet. Accessed April 28, 2014.] Available from: www.scb.se
8. 8.↵
   1. Watts R,
   2. Lane S,
   3. Hanslik T,
   4. Hauser T,
   5. Hellmich B,
   6. Koldingsnes W,
   7. et al.

   Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–7.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Luqmani RA,
   2. Bacon PA,
   3. Moots RJ,
   4. Janssen BA,
   5. Pall A,
   6. Emery P,
   7. et al.

   Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671–8.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Franssen C,
    2. Gans R,
    3. Kallenberg C,
    4. Hageluken C,
    5. Hoorntje S

    . Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998;244:209–16.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Jennette JC,
    2. Wilkman AS,
    3. Falk RJ

    . Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921–30.

    OpenUrlPubMed
12. 12.↵
    1. Weidner S,
    2. Geuss S,
    3. Hafezi-Rachti S,
    4. Wonka A,
    5. Rupprecht HD

    . ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004;19:1403–11.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Hogan SL,
    2. Nachman PH,
    3. Wilkman AS,
    4. Jennette JC,
    5. Falk RJ

    . Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23–32.

    OpenUrlAbstract
14. 14.↵
    1. de Lind van Wijngaarden RA,
    2. Hauer HA,
    3. Wolterbeek R,
    4. Jayne DR,
    5. Gaskin G,
    6. Rasmussen N,
    7. et al.

    Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006;17:2264–74.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Schonermarck U,
    2. Lamprecht P,
    3. Csernok E,
    4. Gross WL

    . Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 2001;40:178–84.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Geffriaud-Ricouard C,
    2. Noel LH,
    3. Chauveau D,
    4. Houhou S,
    5. Grunfeld JP,
    6. Lesavre P

    . Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993;39:125–36.

    OpenUrlPubMed
17. 17.↵
    1. Falk RJ,
    2. Hogan S,
    3. Carey TS,
    4. Jennette JC

    . Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990;113:656–63.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Franssen CF,
    2. Gans RO,
    3. Arends B,
    4. Hageluken C,
    5. ter Wee PM,
    6. Gerlag PG,
    7. et al.

    Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int 1995;47:193–9.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Westman KW,
    2. Bygren PG,
    3. Olsson H,
    4. Ranstam J,
    5. Wieslander J

    . Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842–52.

    OpenUrlAbstract
20. 20.↵
    1. de Joode AA,
    2. Sanders JS,
    3. Stegeman CA

    . Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013;8:1709–17.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Hauer HA,
    2. Bajema IM,
    3. van Houwelingen HC,
    4. Ferrario F,
    5. Noel LH,
    6. Waldherr R,
    7. et al.

    Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80–9.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Mohammad AJ,
    2. Bakoush O,
    3. Sturfelt G,
    4. Segelmark M

    . The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol 2009;38:268–75.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Berden AE,
    2. Ferrario F,
    3. Hagen EC,
    4. Jayne DR,
    5. Jennette JC,
    6. Joh K,
    7. et al.

    Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628–36.

    OpenUrlAbstract/FREE Full Text
24. 24.
    1. Vizjak A,
    2. Rott T,
    3. Koselj-Kajtna M,
    4. Rozman B,
    5. Kaplan-Pavlovcic S,
    6. Ferluga D

    . Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis 2003;41:539–49.

    OpenUrlCrossRefPubMed
25. 25.
    1. Rihova Z,
    2. Jancova E,
    3. Merta M,
    4. Rysava R,
    5. Reiterova J,
    6. Zabka J,
    7. et al.

    Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005;28:144–52.

    OpenUrlCrossRefPubMed
26. 26.
    1. Flossmann O,
    2. Berden A,
    3. de Groot K,
    4. Hagen C,
    5. Harper L,
    6. Heijl C,
    7. et al.

    Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94.

    OpenUrlAbstract/FREE Full Text